Cumulative incidence of SARS‐CoV‐2 infection in the general population of the Valencian Community (Spain) after the surge of the Omicron BA.1 variant

Studies investigating the cumulative incidence of and immune status against SARS‐CoV‐2 infection provide valuable information for shaping public health decision‐making. A cross‐sectional study on 935 participants, conducted in the Valencian Community (VC), measuring anti‐SARS‐CoV‐2‐receptor binding...

Full description

Saved in:
Bibliographic Details
Published inJournal of medical virology Vol. 95; no. 1; pp. e28284 - n/a
Main Authors Camacho, Jorge, Giménez, Estela, Albert, Eliseo, Zulaica, Joao, Álvarez‐Rodríguez, Beatriz, Torres, Ignacio, Rusu, Luciana, Burgos, Javier S., Peiró, Salvador, Vanaclocha, Hermelinda, Limón, Ramón, Alcaraz, María Jesús, Sánchez‐Payá, José, Díez‐Domingo, Javier, Comas, Iñaki, Gonzáles‐Candelas, Fernando, Geller, Ron, Navarro, David
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.01.2023
John Wiley and Sons Inc
Subjects
Antibodies
Antibodies, Neutralizing
Antibodies, Viral
CD4 antigen
CD8 antigen
CD8-Positive T-Lymphocytes
COVID-19 - epidemiology
Cross-Sectional Studies
cumulative incidence of SARS‐CoV‐2 infection
Decision making
Electrochemiluminescence
Enumeration
Humans
Immune status
Incidence
Infections
Lymphocytes
Lymphocytes T
neutralizing antibodies
Nucleocapsids
Public health
Quantitation
SARS-CoV-2 - genetics
SARS‐CoV‐2
seroprevalence
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Spain - epidemiology
T cells
Vaccination
Vaccines
Virology
γ-Interferon
Spain
seroprevalence
neutralizing antibodies
SARS-CoV-2
cumulative incidence of SARS-CoV-2 infection
T cells
Online AccessGet full text

Cover

More Information
Summary:Studies investigating the cumulative incidence of and immune status against SARS‐CoV‐2 infection provide valuable information for shaping public health decision‐making. A cross‐sectional study on 935 participants, conducted in the Valencian Community (VC), measuring anti‐SARS‐CoV‐2‐receptor binding domain‐RBD‐total antibodies and anti‐Nucleocapsid (N)‐IgGs via electrochemiluminescence assays. Quantitation of neutralizing antibodies (NtAb) against ancestral and Omicron BA.1 and BA.2 variants and enumeration of SARS‐CoV‐2‐S specific‐IFNγ‐producing CD4+ and CD8+ T cells was performed in 100 and 137 participants, respectively. The weighted cumulative incidence was 51.9% (95% confidence interval [CI]: 48.7–55.1) and was inversely related to age. Anti‐RBD total antibodies were detected in 97% of participants; vaccinated and SARS‐CoV‐2‐experienced (VAC‐ex; n = 442) presented higher levels (p < 0.001) than vaccinated/naïve (VAC‐n; n = 472) and nonvaccinated/experienced (UNVAC‐ex; n = 63) subjects. Antibody levels correlated inversely with time elapsed since last vaccine dose in VAC‐n (Rho, −0.52; p < 0.001) but not in VAC‐ex (rho −0.02; p = 0.57). Heterologous booster shots resulted in increased anti‐RBD antibody levels compared with homologous schedules in VAC‐n, but not in VAC‐ex. NtAbs against Omicron BA.1 were detected in 94%, 75%, and 50% of VAC‐ex, VAC‐n and UNVAC‐ex groups, respectively. For Omicron BA.2, the figures were 97%, 84%, and 40%, respectively. SARS‐CoV‐2‐S‐reactive IFN‐γ T cells were detected in 73%, 75%, and 64% of VAC‐ex, VAC‐n and UNVAC‐ex, respectively. Median frequencies for both T‐cell subsets were comparable across groups. In summary, by April 2022, around half of the VC population had been infected with SARS‐CoV‐2 and, due to extensive vaccination, displayed hybrid immunity.
Bibliography:Burgos JS (General Directorate of Research and Healthcare Supervision, Department of Health, Valencia Government, Valencia, Spain); Meneu de Guillerna R (Vice‐President Foundation Research Institute in Public Services, Valencia, Spain); Vanaclocha Luna H (General Directorate of Public Health, Department of Health, Valencia Government, Valencia, Spain); Burks DJ (The Prince Philip Research Center‐CIPF‐, Valencia, Spain; Cervantes A (INCLIVA Health Research Institute, Valencia, Spain); Comas I (Biomedicine Institute of Valencia, Spanish Research Council (CSIC); Díez‐Domingo J (Foundation for the promotion of health and biomedical research of the Valencian Community‐FISABIO‐, Valencia, Spain); Peiro S (Foundation for the promotion of health and biomedical research of the Valencian Community‐FISABIO‐, Valencia, Spain); González‐Candelas F (CIBER in Epidemiology and Public Health, Spain; Joint Research Unit “Infection and Public Health” FISABIO‐University of Valencia, Valencia, Spain; Institute for Integrative Systems Biology (I2SysBio), CSIC‐University of Valencia, Valencia, Spain); Ferrer Albiach C (Castelló Provincial Hospital Foundation); Cervantes A (INCLIVA Health Research Institute, Valencia, Spain); Redón J (INCLIVA Health Research Institute, Valencia, Spain); Sánchez‐Payá J (Preventive Medicine Service, Alicante General and University Hospital, Alicante, Spain; Alicante Institute of Health and Biomedical Research (ISABIAL), Alicante, Spain; Sanz G (Instituto de Investigación Sanitaria La Fe); Sempere JM (Biotechnology Department, University of Alicante, Spain); Zapater Latorre E (Foundation of the General University Hospital of Valencia); Navarro D (Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain; Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain).
Members of the Valencian vaccine research program (ProVaVac) study group
Jorge Camacho and Estela Giménez contributed equally to this study.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Members of the Valencian vaccine research program (ProVaVac) study group: Burgos JS (General Directorate of Research and Healthcare Supervision, Department of Health, Valencia Government, Valencia, Spain); Meneu de Guillerna R (Vice‐President Foundation Research Institute in Public Services, Valencia, Spain); Vanaclocha Luna H (General Directorate of Public Health, Department of Health, Valencia Government, Valencia, Spain); Burks DJ (The Prince Philip Research Center‐CIPF‐, Valencia, Spain; Cervantes A (INCLIVA Health Research Institute, Valencia, Spain); Comas I (Biomedicine Institute of Valencia, Spanish Research Council (CSIC); Díez‐Domingo J (Foundation for the promotion of health and biomedical research of the Valencian Community‐FISABIO‐, Valencia, Spain); Peiro S (Foundation for the promotion of health and biomedical research of the Valencian Community‐FISABIO‐, Valencia, Spain); González‐Candelas F (CIBER in Epidemiology and Public Health, Spain; Joint Research Unit “Infection and Public Health” FISABIO‐University of Valencia, Valencia, Spain; Institute for Integrative Systems Biology (I2SysBio), CSIC‐University of Valencia, Valencia, Spain); Ferrer Albiach C (Castelló Provincial Hospital Foundation); Cervantes A (INCLIVA Health Research Institute, Valencia, Spain); Redón J (INCLIVA Health Research Institute, Valencia, Spain); Sánchez‐Payá J (Preventive Medicine Service, Alicante General and University Hospital, Alicante, Spain; Alicante Institute of Health and Biomedical Research (ISABIAL), Alicante, Spain; Sanz G (Instituto de Investigación Sanitaria La Fe); Sempere JM (Biotechnology Department, University of Alicante, Spain); Zapater Latorre E (Foundation of the General University Hospital of Valencia); Navarro D (Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain; Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain).
ISSN:0146-6615
1096-9071
1096-9071
DOI:10.1002/jmv.28284